All In Biotech

Free tool

FAERS Monitor: Ocuflox

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019921 or its brand name (Ocuflox, Ofloxacin). Reports on generic versions are filed under their own applications.

Reports

7,237

Serious

5,537

77% of reports

Hospitalization

2,690

Death reported

615

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain366
  • drug ineffective349
  • off label use318
  • headache291
  • pain274
  • fatigue272
  • arthralgia260
  • nausea257
  • diarrhoea252
  • acute kidney injury248
  • anxiety215
  • pyrexia213
  • renal failure213
  • dyspnoea211
  • chronic kidney disease194

Reports by year received

View as table
YearReports
2004131
2005103
200698
200796
2008111
2009141
201093
2011203
2012242
2013151
2014154
2015218
2016289
2017375
2018531
2019594
2020546
2021582
2022617
2023640
2024508
2025499
2026314

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal36619.017.26,189
chronic kidney diseaseSignal1947.46.51,076
acute kidney injurySignal2484.74.2727
renal failureSignal2134.74.1613
anxietySignal2152.21.9141
arthralgia2601.81.697
pyrexia2131.81.675
headache2911.31.227
pain2741.31.219
diarrhoea2521.11.04
dyspnoea2111.10.91
off label use3181.10.91
fatigue2721.00.90
nausea2570.90.81
drug ineffective3490.80.725

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.